(Q44408279)

2 December 2017

title

Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low? (English)

1 reference

2 December 2017

4

Alison P Galvani

1 reference

2 December 2017

1

Chris T Bauch

1 reference

2 December 2017

Meng Li

2

1 reference

2 December 2017

Gretchen Chapman

series ordinal

3

1 reference

2 December 2017

publication date

1 February 2010

1 reference

Lancet Infectious Diseases

2 December 2017

published in

1 reference

2 December 2017

volume

10

1 reference

2 December 2017

issue

2

1 reference

2 December 2017

page(s)

133-137

1 reference

Human papillomavirus vaccines

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Screening for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Chapter 19: Cost-effectiveness of cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Human papillomavirus and Papanicolaou tests to screen for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Learning from evidence in a complex world.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Multiparameter Calibration of a Natural History Model of Cervical Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Model for assessing human papillomavirus vaccination strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Evaluating human papillomavirus vaccination programs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Chapter 5: Updating the natural history of HPV and anogenital cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Uses and abuses of mathematics in biology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Prevalence of HPV infection among females in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Chapter 13: Current findings from prophylactic HPV vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970004-9

7 January 2021

10.1016/S1473-3099(10)70004-9

Identifiers

DOI

1 reference

2 December 2017

1 reference